Study of a new drug for blood cancers that returned or did not respond
Part of Blood & lymphatic, Cancer clinical trials.
This study tests an investigational drug called MEN2312 for people with acute myeloid leukemia (AML), a type of blood cancer, that has either come back or hasn't improved with treatment. The goal is to see if the drug can help control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have acute myeloid leukemia (AML) that has returned or not responded to treatment.
- Your white blood cell count should be below a certain level before starting.
- Your kidneys, liver, and heart need to be working well enough.
- You should be able to take care of yourself and be up and about (ECOG score of 2 or less).
- You have recovered from serious side effects of previous cancer treatments.
- You have not had a KAT6 inhibitor (this type of drug) before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called CG009301 for people with blood cancers that have come back or haven't responded to standard treatments. The goal is to see if the drug is safe and works against these cancers.
This trial tests a new drug for people with acute myeloid leukemia (AML) that has come back or hasn't responded to standard therapies, and whose leukemia has certain genetic markers. The drug may target these specific changes to help stop the cancer.
This early-phase study tests a menin inhibitor drug (SNDX-5613) combined with standard induction chemotherapy (daunorubicin plus cytarabine) in newly diagnosed AML with specific gene changes (NPM1 or FLT3 status, or MLL/KMT2A or NUP98). It may help patients whose AML has these genetic features respond better to intensive treatment.
This Phase 1/2 study tests enzomenib (DSP-5336) in people with relapsed or hard-to-treat acute leukemia (and, in some places, certain other blood cancers). The goal is to see how the drug works and how safe it is, especially for leukemia cases with specific genetic changes (KMT2A/MLL or NPM1).
This study tests an experimental drug called TCB008 given through an IV. It is for people with acute myeloid leukemia (AML) or a related condition called MDS/AML that has come back or not gone away after prior treatment. The goal is to see if the drug is safe and if it helps.
This trial tests a new drug, FD-001, for people with certain blood cancers (like leukemia, lymphoma, or myeloma) that have come back or stopped responding to standard treatments. The goal is to see if the drug is safe and how well it might work.
Hear when a new Hematological Malignancy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.